Corbus Pharma Reports Positive Top-Line Data From Weight-Loss Drug Study
By Kelly Cloonan
Corbus Pharmaceuticals said top-line data from a study for an obesity treatment demonstrated statistically significant and clinically meaningful weight loss.
The clinical-stage company said Monday a 60-milligram dose of its CRB-913 drug showed a mean weight loss of 5% at 12 weeks in a Phase 1b trial.
The once-daily oral treatment also showed fewer gastrointestinal adverse events based on cross-trial comparison with published data of currently marketed oral GLP-1 drugs, the company said.
The data supports the treatment's potential to establish a new class of oral, nonincretin obesity medicines, the company said.
The company plans to work with the Food and Drug Administration on a clinical-development plan for the drug and expects to initiate a Phase 2 monotherapy study in the first half of 2027. The company said it is also evaluating the potential to combine CRB-913 with GLP-1 therapy.
Shares were up 5.2% to $8.54 in premarket trading.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
September 14, 2026 08:31 ET (12:31 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States